MedTrace Logo

Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract

NCT03641248 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2022-05-26

No results posted yet for this study

Summary

Study will define the bioavailability and short term pharmacokinetics of the principal secondary metabolites of a aqueous-ethanolic extract of H. procumbens in non-enteric and enteric capsules.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

Enteric coated Devil's Claw

Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside

DRUG

Non-enteric coated Devil's Claw

Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside

Sponsors & Collaborators

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • William Folk, PhD · Univ of Missouri

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2021-07-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03641248 on ClinicalTrials.gov